Genetic polymorphism analysis of cytochrome P450 2C19 among gender,age and body mass index in Chinese Han population

Abstract

Abstract: AIM: To identify the distribution feature of cytochrome P450 2C19 (CYP2C19)gene, and assess the effects of gender, age (18-80 years old)and body weight on genetic polymorphism of CYP2C19 in a Chinese Han population.METHODS: Two hundred and eightthree unrelated, healthy Chinese Han population subjects (126 males and 157 females, aged from 18 to 80)were genotyped for CYP2C19 to identify the wild-type (CYP2C19 *1)gene and two mutations (CYP2C19 *2 CYP2C19 *3) by PCR and DNA sequencing.RESULTS: Six different allelic variants of CYP2C19 gene were observed in this study.42.4 %(120 of the 283 subjects) were homozygous for the wild type CYP2C19 *1 * 1 in total by the genotyping analysis.The frequencies of the CYP2C19 *2 and *3 alleles were 29.2 % and 6.7 % respectively.14.2 % (40 of 283 subjects)were genotypically identified as PMs of CYP2C19.Of 126 genotyped male subjects, the CYP2C19 *2 and *3 allele frequencies were 28.2 %and 5.2 %.And among the 157 female subjects, the frequencies of the two alleles were 29.9 % and 8.0 %.The frequencies of CYP2C19 *2 and CYP2C19 *3 alleles in different ages were 29.9 % and 6.8 % (18 to 45 years old)versus 28.1 % and 6.6 % (no less than 45 years old).Body mass index (BMI)is an optimal way to examine obesity rather than actual body weight.BMI>25 indicates the individual is overweight. The frequencies of the CYP2C19 *2 and *3 alleles were 31.1 % and 6.6 %in BMI <25 group versus 22.7 %and 7 % in BMI>25 group.CONCLUSION: There are no statistically significant difference in the occurrence of CYP2C19 *2 and CYP2C19 *3 among gender (P>0.05), age (P>0.05)and BMI (P>0.05).So gender, age and BMI may have no significant effect on genetic polymorphism of CYP2C19.

Key words: CYP2C19, gentic polymorphism, allele

CLC Number:

R968

ZHOU Jian, LV Hong, KANG Xi-xiong. Genetic polymorphism analysis of cytochrome P450 2C19 among gender,age and body mass index in Chinese Han population[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 208-213.

References

[1] Wroblewski B, Glenn MB.The cytochrome P450 drug metabolizing enzyme system:an overview of potential clinicially important drug interactions[J]. J Head Trauma Rebabil, 2002;17:571-574.
[2] Wedlund PJ, Aslanian WS, McAllister CB, et al. Mephenytoin hydroxylation deficiency in Caucasians:frequency of a new oxidative drug metabolism polymorphism[J]. Clin Pharmacol Ther,1984;36:773-780.
[3] Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19:correlation between 2C19 and S-mephenytoin 4'-hydroxylation[J]. Arch Biochem Biophys, 1993;306:240-245.
[4] He N, Yan FX,Huang SL, et al. CYP2C19 genotype and S-me- phenytoin 4'-hydroxy lation phenotype in a Chinese Dai population[J]. Eur J Clin Pharmacol, 2002;58:15-18.
[5] Kimura M, Ieiri I, Mamiya K, et al. Genetic Polymorphism of Cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese Population[J]. Ther Drug Monit, 1998;20:243-247.
[6] Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population[J]. Pharmacogenetics, 1996;6:547-551.
[7] Chang M, Dahl ML, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparision with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype[J]. Pharmacogenetics, 1996;5:358-363.
[8] Persson I, Aklillu E, Rodrigues F, et al. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians[J]. Pharmacogenetics, 1996;6:521-526.
[9] Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele[J]. J Pharmacol Exp Ther, 1997;281:604-609.
[10] 唐莉, 彭林, 张松, 等.中国独龙族人群中细胞色素P4502C19 基因多态性的研究[J]. 中国药理学通报, 2001;17:556-558.
[11] 张松, 周强, 董兆文.中国苗族人群中细胞色素P4502C19基因多态性的研究[J]. 遗传HEREDITAS, 2001;23:192-194.
[12] 丁华文, 董兆文, 姜祖刚, 等.104 名藏族志愿者中细胞色素P4502C19m1 的基因多态性[J]. 遗传HEREDITAS,2004;26:151-154.
[13] 段于峰, 武占鹏, 张松, 等.中国土族人群中细胞色素P4502C19 基因多态性的研究[J]. 中国优生与遗传杂志,2001;9:13-14.
[14] 张松, 董兆文, 唐莉, 等.中国苗族、布依族、土族和独龙族群体中细胞色素P4502C19 基因座遗传多态性分析[J]. 中华医学遗传学杂志, 2002;19:52-54.
[15] 牛春燕, 罗金燕.中国汉族人群细胞色素P450 酶CYP2C19 基因多态性分析[J]. 中华实用医药杂志, 2003;3:1355-1358.
[16] Shimizu T, Ochiai H, Asell F, et al. Bioinformatics Research on Inter-racial Difference in Drug Metabolism I.Analy sis on Frequencies of Mutant Alleles and Poor Metabolizers on CYP2D6 and CYP2C19[J]. Drug Metab Pharmacokinet, 2003;18:48-70.
[17] Xie HG, Huang SL, Xu ZH, et al. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylation (CYP2C19) in a Chinese population[J]. Pharmacogenetics, 1997;7:115-119.
[18] 付良青, 黄丰, 吴德政, 等.中国汉族人群不同性别细胞色素氧化酶CYP2C19 基因多态性的比较[J]. 药学学报, 2004;39:161-163.
[19] 丁晖, 黄越, 王维治, 等.中国人CYP2C19 和2C9 等位基因多态性分析[J]. 哈尔滨医药, 2002;2:1-3.